News

In part 2 of this 5-part series, Lerma and Lala-Trindade discuss the key differences in MoA for nsMRA and MRAs.

In this first of this 5-part series, Lerma and Lala-Trindade discuss the interplay between chronic kidney disease and cardiovascular disease.

Yee discussed research she is conducting into gFSGS and nephrotic syndrome, presented at ASN Kidney Week.

These data suggest brodalumab’s safety profile is consistent with findings from long-term clinical trials, with no new occurrences of suicide and a low rate of fungal infection.

Sexual trauma and genetic risk independently and together raise mental illness risk, a new study found.

Abdellatif discussed the high prevalence of gout in patients with chronic kidney disease and the importance of screening and early treatment.

Open-label, interim data from ASSURE shows positive effect and tolerability with once-daily seladelpar in patients with primary biliary cholangitis and compensated cirrhosis.

A decade after bariatric surgery, most teens maintained weight loss and reduced obesity-related conditions such as type 2 diabetes and hypertension.

Popov reviews findings from her late-breaking presentation at ACG 2024 suggesting GLP-1 RAs may not need to be held prior to upper endoscopy.

In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, with a focus on updates related to atrasentan.

In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, with a focus on felzartamab.

In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, particularly data on long-term use of Nefecon.

In this segment, Barratt reflects on recent updates from the SPARTAN trial examining use of sparsentan as a first-line therapy in IgAN.

In this segment, Barratt reflects on recent updates in the management of IgA nephropathy.

Zand discussed the unmet need for refractory primary FSGS and the importance of investigations specifically in this population.

This interview at the Fall Clinical Dermatology Conference features a discussion with Stein Gold regarding the open-label extension of the phase 3 ADORING trial regarding tapinarof.

Iyer reviews findings from subgroup analyses of the phase 3 STARS study of apraglutide for SBS-IF based on demographics and disease characteristics.

Many with moderate-to-severe atopic dermatitis do not reach treatment targets in 12 months, underscoring a need for proactive management strategies.

Dellon reviews phase 3 data supporting the 48-week safety and efficacy of cendakimab for treating EoE.

A retrospective review of a community-based practice provides insights into navigating setbacks in IBD care initiation due to insurance requirements.

A qualitative / quantitative study shows significant gaps in PBC diagnosis confidence and skill between care providers.

Only about 2% of eligible patients with ALD have received a pharmacotherapy for alcohol use disorder—and the prescription takes more than a year to receive.

Complete, 24-month data from the IGNAZ study were presented at the ASN Kidney Week 2024 Meeting.

Mayo explains elafibranor’s benefit for patients with advanced-stage primary biliary cholangitis based on findings from a new ELATIVE analysis.

Iyer describes differences between short bowel syndrome and intestinal failure and explains the value of GLP-2 analogs like apraglutide for treatment.

A study revealed using language models as diagnostic aids did not significantly enhance clinical reasoning or accuracy among physicians over conventional resources alone.

Stein Gold speaks in this interview about the new lebrikizumab (Ebglyss) data presented at the Fall Clinical Dermatology Conference.

Sands reviews long-term phase 3 data from the LUCENT-3 and VIVID-2 extension studies of mirikizumab in UC and CD presented at ACG 2024.